You are here
Beyond diagnosis, management of neuropsychiatric lupus (NPSLE) can be challenging. Moreover, there are scant studies addressing optimal management. In this issue of Clinical Rheumatology, researchers show the efficacy of mycophenolate mofetil (MMF) and deflazacort in NPSLE.
They identified 140 patients with NPSLE; 88 fulfilled the inclusion criteria. Most were young (25.51 ± 7.82 years) and female, and the median duration of follow-up was 33 months (3–129 months).
Seizures were the most common NPSLE manifestation (42%). After removing patients antiphospholipid syndrome, it was shown that the remaining 70 patients improved 87% with therapy.
At last follow-up, 97.1% with detailed data had improved, while 2 patients had relapsed on this regimen. Side effects were significantly more common in patients on prednisolone as compared to those on deflazacort.
In patients with NPSLE, MMF along with tapering steroids is an efficacious combo in inducing remission and preventing relapse of disease.